Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Cited by (1,051)

Items 101–200 of 1,051

1. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
   Marcus, Leigh, Lemery, Steven J., Keegan, Patricia, Pazdur, Richard · 2019 · Clinical Cancer Research
2. Therapeutic cancer vaccines
   Cornelis J.M. Melief, Thorbald van Hall, Ramon Arens, FERRY A. OSSENDORP, Sjoerd H. van der Burg · 2015 · Journal of Clinical Investigation
3. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
   Danny N. Khalil, Eric L. Smith, Renier J. Brentjens, Jedd D. Wolchok · 2016 · Nature Reviews Clinical Oncology
4. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
   David R. Gandara, Sarah M. Paul, Marcin Kowanetz, Erica Schleifman, Wei Zou, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Geoff A. Otto, Christine M. Malboeuf et al. · 2018 · Nature Medicine
5. The lung microenvironment: an important regulator of tumour growth and metastasis
   Nasser Khaled Altorki, Geoffrey J. Markowitz, Dingcheng Gao, Jeffrey L. Port, Ashish Saxena, Brendon Matthew Stiles, Timothy E. McGraw, Vivek Mittal · 2018 · Nature reviews. Cancer
6. Personalized vaccines for cancer immunotherapy
   Uğur Şahin, Özlem Türeci · 2018 · Science
7. Toward personalized treatment approaches for non-small-cell lung cancer
   Meina Wang, Roy S. Herbst, Chris Boshoff · 2021 · Nature Medicine
8. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
   Hegde, Priti S., Karanikas, Vaios, Evers, Stefan · 2016 · Clinical Cancer Research
9. Lung cancer immunotherapy: progress, pitfalls, and promises
   Lahiri, Aritraa, Maji, Avik, Potdar, Pravin D., Singh, Navneet, Parikh, Purvish, Bisht, Bharti, Mukherjee, Anubhab, Paul, Manash K. · 2023 · Molecular Cancer
10. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
    Aadel A. Chaudhuri, Jacob J. Chabon, Alexander F. Lovejoy, Aaron M. Newman, Henning Stehr, Tej Deepak Azad, Michael Siavash Khodadoust, Mohammad Shahrokh Esfahani, Chih Long Liu, Li Zhou et al. · 2017 · Cancer Discovery
11. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
    Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas, Yang Feng, Dimiter Stanchev Dimitrov, David Randolph Jones, Michel Sadelain, Prasad S. Adusumilli · 2016 · Journal of Clinical Investigation
12. Towards personalized, tumour-specific, therapeutic vaccines for cancer
    Hu, Zhuting, Ott, Patrick A., Wu, Catherine J. · 2018 · Nature Reviews Immunology
13. Oesophageal cancer
    Elizabeth Catherine Smyth, Jesper Lagergren, Rebecca Claire Fitzgerald, Florian Lordick, Manish A. Shah, Pernilla Lagergren, David Cunningham · 2017 · Nature Reviews Disease Primers
14. Genomic and Functional Approaches to Understanding Cancer Aneuploidy
    Alison Marie Taylor, Juliann Shih, Gavin Ha, Galen F. Gao, Xiaoyang Zhang, Ashton C. Berger, Steven E. Schumacher, Chen Wang, Hai Hu, Jianfang Liu et al. · 2018 · Cancer Cell
15. A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
    Barry, Kevin C., Hsu, Joy, Broz, Miranda L., Cueto, Francisco J., Binnewies, Mikhail, Combes, Alexis J., Nelson, Amanda E., Loo, Kimberly, Kumar, Raj, Rosenblum, Michael D. et al. · 2018 · Nature Medicine
16. Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer
    Kathryn Cecilia Arbour, Gregory J. Riely · 2019 · JAMA
17. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
    Braun, David A., Hou, Yue, Bakouny, Ziad, Ficial, Miriam, Sant’ Angelo, Miriam, Forman, Juliet, Ross-Macdonald, Petra, Berger, Ashton C., Jegede, Opeyemi A., Elagina, Liudmilla et al. · 2020 · Nature Medicine
18. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
    Viktor A. Adalsteinsson, Gavin Ha, Samuel S. Freeman, Atish Dipankar Choudhury, Daniel G. Stover, Heather Anne Parsons, Gregory Gydush, Sarah C. Reed, Denisse Rotem, Justin Rhoades et al. · 2017 · Nature Communications
19. Targeting neoantigens to augment antitumour immunity
    Yarchoan, Mark, Johnson, Burles A., Lutz, Eric R., Laheru, Daniel A., Jaffee, Elizabeth M. · 2017 · Nature Reviews Cancer
20. Targeting metastatic cancer
    Karuna Ganesh, Joan Massagué · 2021 · Nature Medicine
21. CD8+ T cell differentiation and dysfunction in cancer
    Philip, Mary, Schietinger, Andrea · 2022 · Nature Reviews Immunology
22. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
    Jonathan M. Pitt, Marie Vétizou, Romain Daillère, María Paula Roberti, Takahiro Yamazaki, Bertrand Routy, Patricia Lepage, Ivo Gomperts Boneca, Mathias Chamaillard, Guido Kroemer et al. · 2016 · Immunity
23. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
    Liu, David, Schilling, Bastian, Liu, Derek, Sucker, Antje, Livingstone, Elisabeth, Jerby-Arnon, Livnat, Zimmer, Lisa, Gutzmer, Ralf, Satzger, Imke, Loquai, Carmen et al. · 2019 · Nature Medicine
24. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
    Daniel James McGrail, P.G. Pilié, N.U. Rashid, Leonie Voorwerk, Maarten Slagter, Marleen Kok, Eric W. Jonasch, Mustafa Khasraw, A.B. Heimberger, Bora Lim et al. · 2021 · Annals of Oncology
25. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
    Chen, Pei-Ling, Roh, Whijae, Reuben, Alexandre, Cooper, Zachary A., Spencer, Christine N., Prieto, Peter A., Miller, John P., Bassett, Roland L., Gopalakrishnan, Vancheswaran, Wani, Khalida et al. · 2016 · Cancer Discovery
26. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
    Blass, Eryn, Ott, Patrick A. · 2021 · Nature Reviews Clinical Oncology
27. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
    Conforti, Fabio, Pala, Laura, Bagnardi, Vincenzo, De Pas, Tommaso, Martinetti, Marco, Viale, Giuseppe, Gelber, Richard D, Goldhirsch, Aron · 2018 · The Lancet Oncology
28. T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
    Ott, Patrick A., Bang, Yung-Jue, Piha-Paul, Sarina A., Razak, Albiruni R. Abdul, Bennouna, Jaafar, Soria, Jean-Charles, Rugo, Hope S., Cohen, Roger B., O’Neil, Bert H., Mehnert, Janice M. et al. · 2019 · Journal of Clinical Oncology
29. Monitoring immune-checkpoint blockade: response evaluation and biomarker development
    Nishino, Mizuki, Ramaiya, Nikhil H., Hatabu, Hiroto, Hodi, F. Stephen · 2017 · Nature Reviews Clinical Oncology
30. Lung cancer: Biology and treatment options
    Hassan Lemjabbar‐Alaoui, Omer Ul Hassan, Yiwei Yang, Petra C. Buchanan · 2015 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
31. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
    Stefan Diem, Sabine Schmid, Mirjam Krapf, Lukas Flatz, Diana Born, Wolfram Jochum, Arnoud J. Templeton, Martin Früh · 2017 · Lung Cancer
32. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
    Andrea Cossarizza, Hyun‐Dong Chang, Andreas Radbruch, Andreas Acs, Dieter Adam, Sabine Adam‐Klages, William W. Agace, Nima Aghaeepour, Mübeccel Akdiş, Matthieu Allez et al. · 2019 · European Journal of Immunology
33. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
    Garris, Christopher S., Arlauckas, Sean P., Kohler, Rainer H., Trefny, Marcel P., Garren, Seth, Piot, Cécile, Engblom, Camilla, Pfirschke, Christina, Siwicki, Marie, Gungabeesoon, Jeremy et al. · 2018 · Immunity
34. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
    Hellmann, Matthew D, Rizvi, Naiyer A, Goldman, Jonathan W, Gettinger, Scott N, Borghaei, Hossein, Brahmer, Julie R, Ready, Neal E, Gerber, David E, Chow, Laura Q, Juergens, Rosalyn A et al. · 2017 · The Lancet Oncology
35. Acquired Resistance to Immune Checkpoint Inhibitors
    Adam Jacob Schoenfeld, Matthew David Hellmann · 2020 · Cancer Cell
36. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures
    Yasin Şenbabaoğlu, Ron S. Gejman, Andrew G. Winer, Ming Liu, Eliezer M. Van Allen, Guillermo de Velasco, Diana Miao, Irina Ostrovnaya, Esther N Drill, Augustin Luna et al. · 2016 · Genome biology
37. Chromatin states define tumour-specific T cell dysfunction and reprogramming
    Philip, Mary, Fairchild, Lauren, Sun, Liping, Horste, Ellen L., Camara, Steven, Shakiba, Mojdeh, Scott, Andrew C., Viale, Agnes, Lauer, Peter, Merghoub, Taha et al. · 2017 · Nature
38. Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
    Dong, Zhong-Yi, Zhong, Wen-Zhao, Zhang, Xu-Chao, Su, Jian, Xie, Zhi, Liu, Si-Yang, Tu, Hai-Yan, Chen, Hua-Jun, Sun, Yue-Li, Zhou, Qing et al. · 2017 · Clinical Cancer Research
39. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
    Christina Pfirschke, Camilla Engblom, Steffen Rickelt, Virna Cortez‐Retamozo, Christopher Garris, Ferdinando Pucci, Takahiro Yamazaki, Vichnou Poirier-Colame, Andita Newton, Younes Redouane et al. · 2016 · Immunity
40. Cancer nanomedicine for combination cancer immunotherapy
    Jutaek Nam, Sejin Son, Kyong Soo Park, Weiping Zou, Lonnie D. Shea, James Jaehyun Moon · 2019 · Nature Reviews Materials
41. Microsatellite Instability as a Biomarker for PD-1 Blockade
    Jonathan C. Dudley, Ming‐Tseh Lin, Dung Thi Le, James R. Eshleman · 2016 · Clinical Cancer Research
42. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
    Litchfield, Kevin, Reading, James L., Puttick, Clare, Thakkar, Krupa, Abbosh, Chris, Bentham, Robert, Watkins, Thomas B.K., Rosenthal, Rachel, Biswas, Dhruva, Rowan, Andrew et al. · 2021 · Cell
43. Dendritic cell-based immunotherapy
    Rachel Lubong Sabado, Sreekumar Balan, Nina Bhardwaj · 2016 · Cell Research
44. Current Challenges in Cancer Treatment
    Jon Zugazagoitia, Cristiano Guedes, Santiago Ponce, Irene Ferrer, Sonia Molina‐Pinelo, Luis G Paz-Ares · 2016 · Clinical Therapeutics
45. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
    Roh, Whijae, Chen, Pei-Ling, Reuben, Alexandre, Spencer, Christine N., Prieto, Peter A., Miller, John P., Gopalakrishnan, Vancheswaran, Wang, Feng, Cooper, Zachary A., Reddy, Sangeetha M. et al. · 2017 · Science Translational Medicine
46. Radiotherapy induces responses of lung cancer to CTLA-4 blockade
    Formenti, Silvia C., Rudqvist, Nils-Petter, Golden, Encouse, Cooper, Benjamin, Wennerberg, Erik, Lhuillier, Claire, Vanpouille-Box, Claire, Friedman, Kent, Ferrari de Andrade, Lucas, Wucherpfennig, Kai W. et al. · 2018 · Nature Medicine
47. Molecular profiling for precision cancer therapies
    Eoghan Ruadh Malone, Marc Oliva, Peter J. B. Sabatini, Tracy L. Stockley, Lillian L. Siu · 2020 · Genome Medicine
48. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
    Kamphorst, Alice O., Pillai, Rathi N., Yang, Shu, Nasti, Tahseen H., Akondy, Rama S., Wieland, Andreas, Sica, Gabriel L., Yu, Ke, Koenig, Lydia, Patel, Nikita T. et al. · 2017 · Proceedings of the National Academy of Sciences
49. Coinhibitory Pathways in Immunotherapy for Cancer
    Susanne H.C. Baumeister, Gordon James Freeman, Glenn Dranoff, Arlene H. Sharpe · 2016 · Annual Review of Immunology
50. β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
    Ruiz de Galarreta, Marina, Bresnahan, Erin, Molina-Sánchez, Pedro, Lindblad, Katherine E., Maier, Barbara, Sia, Daniela, Puigvehi, Marc, Miguela, Verónica, Casanova-Acebes, María, Dhainaut, Maxime et al. · 2019 · Cancer Discovery
51. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
    Samra Turajlic, Kevin Litchfield, Hang Xu, Rachel Rosenthal, Nicholas McGranahan, James L. Reading, Yien Ning Sophia Wong, Andrew Rowan, Nnennaya Kanu, Maise Al Bakir et al. · 2017 · The Lancet Oncology
52. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
    Sha, Dan, Jin, Zhaohui, Budczies, Jan, Kluck, Klaus, Stenzinger, Albrecht, Sinicrope, Frank A. · 2020 · Cancer Discovery
53. Dendritic Cells and Cancer Immunity
    Alycia Gardner, Brian Ruffell · 2016 · Trends in Immunology
54. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
    Leonie Voorwerk, Maarten Slagter, Hugo M. Horlings, Karolina Sikorska, Koen K Van de Vijver, Michiel de Maaker, Iris Nederlof, Roelof J.C. Kluin, Sarah Warren, SuFey Ong et al. · 2019 · Nature Medicine
55. Small-cell lung cancer: what we know, what we need to know and the path forward
    Adi F. Gazdar, Paul A. Bunn, John Dorrance Minna · 2017 · Nature reviews. Cancer
56. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
    Liu, Jing, Blake, Stephen J., Yong, Michelle C.R., Harjunpää, Heidi, Ngiow, Shin Foong, Takeda, Kazuyoshi, Young, Arabella, O'Donnell, Jake S., Allen, Stacey, Smyth, Mark J. et al. · 2016 · Cancer Discovery
57. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
    Zhao, Junfei, Chen, Andrew X., Gartrell, Robyn D., Silverman, Andrew M., Aparicio, Luis, Chu, Tim, Bordbar, Darius, Shan, David, Samanamud, Jorge, Mahajan, Aayushi et al. · 2019 · Nature Medicine
58. MHC-II neoantigens shape tumour immunity and response to immunotherapy
    Alspach, Elise, Lussier, Danielle M., Miceli, Alexander P., Kizhvatov, Ilya, DuPage, Michel, Luoma, Adrienne M., Meng, Wei, Lichti, Cheryl F., Esaulova, Ekaterina, Vomund, Anthony N. et al. · 2019 · Nature
59. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
    Valsamo Anagnostou, Kellie Nicole Smith, Patrick M. Forde, Noushin Niknafs, Rohit Bhattacharya, James Robert White, Theresa Zhang, Vilmos Adleff, Jillian A. Phallen, Neha Wali et al. · 2016 · Cancer Discovery
60. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
    Matthew David Hellmann, Margaret K. Callahan, Mark Magdi Awad, Emiliano Calvo, Paolo A. Ascierto, Akin Atmaca, Naiyer A. Rizvi, Fred R. Hirsch, Giovanni Selvaggi, Joseph D. Szustakowski et al. · 2018 · Cancer Cell
61. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency
    Bouffet, Eric, Larouche, Valérie, Campbell, Brittany B., Merico, Daniele, de Borja, Richard, Aronson, Melyssa, Durno, Carol, Krueger, Joerg, Cabric, Vanja, Ramaswamy, Vijay et al. · 2016 · Journal of Clinical Oncology
62. Clinical relevance of host immunity in breast cancer: from TILs to the clinic
    Savas, Peter, Salgado, Roberto, Denkert, Carsten, Sotiriou, Christos, Darcy, Phillip K., Smyth, Mark J., Loi, Sherene · 2016 · Nature Reviews Clinical Oncology
63. Tumor-infiltrating lymphocytes in the immunotherapy era
    Sterre T. Paijens, Annegé Vledder, Marco de Bruyn, Hans W. Nijman · 2020 · Cellular and Molecular Immunology
64. Therapeutic T cell engineering
    Michel Sadelain, Isabelle Rivière, Stanley R. Riddell · 2017 · Nature
65. Identification of essential genes for cancer immunotherapy
    Patel, Shashank J., Sanjana, Neville E., Kishton, Rigel J., Eidizadeh, Arash, Vodnala, Suman K., Cam, Maggie, Gartner, Jared J., Jia, Li, Steinberg, Seth M., Yamamoto, Tori N. et al. · 2017 · Nature
66. Breast Cancer Immunotherapy: Facts and Hopes
    Leisha A. Emens · 2017 · Clinical Cancer Research
67. Integrative clinical genomics of metastatic cancer
    Robinson, Dan R., Wu, Yi-Mi, Lonigro, Robert J., Vats, Pankaj, Cobain, Erin, Everett, Jessica, Cao, Xuhong, Rabban, Erica, Kumar-Sinha, Chandan, Raymond, Victoria et al. · 2017 · Nature
68. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
    L. Kraehenbuehl, Chien-Huan Weng, S. Eghbali, J. Wolchok, T. Merghoub · 2021 · Nature Reviews Clinical Oncology
69. The Basis of Oncoimmunology
    Palucka, A. Karolina, Coussens, Lisa M. · 2016 · Cell
70. Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis
    Lee, Chee Khoon, Man, Johnathan, Lord, Sally, Links, Matthew, Gebski, Val, Mok, Tony, Yang, James Chih-Hsin · 2017 · Journal of Thoracic Oncology
71. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
    Rafiq, Sarwish, Yeku, Oladapo O, Jackson, Hollie J, Purdon, Terence J, van Leeuwen, Dayenne G, Drakes, Dylan J, Song, Mei, Miele, Matthew M, Li, Zhuoning, Wang, Pei et al. · 2018 · Nature Biotechnology
72. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
    Alena Gros, Maria R. Parkhurst, Eric Tran, Anna Pasetto, Paul F. Robbins, Sadia Ilyas, Todd D. Prickett, Jared J. Gartner, Jessica S. Crystal, Ilana M. Roberts et al. · 2016 · Nature Medicine
73. Tumour evolution in hepatocellular carcinoma
    Amanda J. Craig, Johann von Felden, Teresa García‐Lezana, Samantha Sarcognato, Augusto Villanueva · 2019 · Nature Reviews Gastroenterology & Hepatology
74. Tumour-targeting bacteria engineered to fight cancer
    Zhou, Shibin, Gravekamp, Claudia, Bermudes, David, Liu, Ke · 2018 · Nature Reviews Cancer
75. Intratumoral heterogeneity in cancer progression and response to immunotherapy
    Ilio Vitale, Efrat Shema, Sherene Loi, Lorenzo Galluzzi · 2021 · Nature Medicine
76. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
    Deng, Jiehui, Wang, Eric S., Jenkins, Russell W., Li, Shuai, Dries, Ruben, Yates, Kathleen, Chhabra, Sandeep, Huang, Wei, Liu, Hongye, Aref, Amir R. et al. · 2018 · Cancer Discovery
77. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
    Shona A. Hendry, Roberto Salgado, Thomas Gevaert, Prudence Anne Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen K Van de Vijver, Monica Valeria Estrada, Paula I. González Ericsson et al. · 2017 · Advances in Anatomic Pathology
78. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
    Gettinger, Scott, Choi, Jungmin, Hastings, Katherine, Truini, Anna, Datar, Ila, Sowell, Ryan, Wurtz, Anna, Dong, Weilai, Cai, Guoping, Melnick, Mary Ann et al. · 2017 · Cancer Discovery
79. Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
    Lastwika, Kristin J., Wilson, Willie, Li, Qing Kay, Norris, Jeffrey, Xu, Haiying, Ghazarian, Sharon R., Kitagawa, Hiroshi, Kawabata, Shigeru, Taube, Janis M., Yao, Sheng et al. · 2016 · Cancer Research
80. Opportunities and challenges of radiotherapy for treating cancer
    Schaue, Dörthe, McBride, William H. · 2015 · Nature Reviews Clinical Oncology
81. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
    Shogo Kumagai, Yosuke Togashi, Takahiro Kamada, Eri Sugiyama, Hitomi Nishinakamura, Yoshiko Takeuchi, Vitaly Kochin, Kota Itahashi, Yuka Maeda, Shigeyuki Matsui et al. · 2020 · Nature Immunology
82. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade
    House, Imran G., Savas, Peter, Lai, Junyun, Chen, Amanda X.Y., Oliver, Amanda J., Teo, Zhi L., Todd, Kirsten L., Henderson, Melissa A., Giuffrida, Lauren, Petley, Emma V. et al. · 2020 · Clinical Cancer Research
83. The changing therapeutic landscape of head and neck cancer
    John D. Cramer, Barbara Ann Burtness, Quynh‐Thu Le, Robert Louis Ferris · 2019 · Nature Reviews Clinical Oncology
84. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
    D'Angelo, Sandra P, Mahoney, Michelle R, Van Tine, Brian A, Atkins, James, Milhem, Mohammed M, Jahagirdar, Balkrishna N, Antonescu, Cristina R, Horvath, Elise, Tap, William D, Schwartz, Gary K et al. · 2018 · The Lancet Oncology
85. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer
    Ott, Patrick A., Hu-Lieskovan, Siwen, Chmielowski, Bartosz, Govindan, Ramaswamy, Naing, Aung, Bhardwaj, Nina, Margolin, Kim, Awad, Mark M., Hellmann, Matthew D., Lin, Jessica J. et al. · 2020 · Cell
86. The head and neck cancer immune landscape and its immunotherapeutic implications
    Rajarsi Mandal, Yasin Şenbabaoğlu, Alexis Desrichard, Jonathan J. Havel, Martin G. Dalin, Nadeem Riaz, Ken-Wing Lee, Ian Ganly, A. Ari Hakimi, Timothy An-thy Chan et al. · 2016 · JCI Insight
87. Comprehensive Analysis of Hypermutation in Human Cancer
    Brittany B. Campbell, Nicholas D Light, David A. Fabrizio, Matthew Zatzman, Fabio Fuligni, Richard de Borja, Scott Davidson, Melissa Edwards, Julia Andrea Elvin, Karl P. Hodel et al. · 2017 · Cell
88. Review of precision cancer medicine: Evolution of the treatment paradigm
    Apostolia Maria Tsimberidou, Elena Fountzilas, Mina Nikanjam, Razelle Kurzrock · 2020 · Cancer Treatment Reviews
89. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
    Schietinger, Andrea, Philip, Mary, Krisnawan, Varintra E., Chiu, Edison Y., Delrow, Jeffrey J., Basom, Ryan S., Lauer, Peter, Brockstedt, Dirk G., Knoblaugh, Sue E., Hämmerling, Günter J. et al. · 2016 · Immunity
90. Mechanisms of immunotherapy resistance: lessons from glioblastoma
    Christopher Mitchell Jackson, John Hyunkuk Choi, Michael K. Lim · 2019 · Nature Immunology
91. The “cancer immunogram”
    Blank, Christian U., Haanen, John B., Ribas, Antoni, Schumacher, Ton N. · 2016 · Science
92. Immunogenicity of somatic mutations in human gastrointestinal cancers
    Tran, Eric, Ahmadzadeh, Mojgan, Lu, Yong-Chen, Gros, Alena, Turcotte, Simon, Robbins, Paul F., Gartner, Jared J., Zheng, Zhili, Li, Yong F., Ray, Satyajit et al. · 2015 · Science
93. The clinical role of the TME in solid cancer
    Nicolás A. Giraldo, Rafael Sánchez-Salas, J. David Peske, Yann Alexandre Vano, Étienne Becht, Florent Petitprez, Pierre Validire, Alexandre Ingels, Xavier Cathelineau, Wolf H. Fridman et al. · 2018 · British Journal of Cancer
94. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
    Ezra E.W. Cohen, R. Bryan Bell, Carlo Bruno Bifulco, Barbara Ann Burtness, Maura L. Gillison, Kevin Joseph Harrington, Quynh‐Thu Le, Nancy Y. Lee, Rom S. Leidner, Rebecca L. Lewis et al. · 2019 · Journal for ImmunoTherapy of Cancer
95. Vaccines for established cancer: overcoming the challenges posed by immune evasion
    Sjoerd H. van der Burg, Ramon Arens, FERRY A. OSSENDORP, Thorbald van Hall, Cornelis J.M. Melief · 2016 · Nature reviews. Cancer
96. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
    Shona A. Hendry, Roberto Salgado, Thomas Gevaert, Prudence Anne Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen K Van de Vijver, Monica Valeria Estrada, Paula I. González Ericsson et al. · 2017 · Advances in Anatomic Pathology
97. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry
    Bassani-Sternberg, Michal, Bräunlein, Eva, Klar, Richard, Engleitner, Thomas, Sinitcyn, Pavel, Audehm, Stefan, Straub, Melanie, Weber, Julia, Slotta-Huspenina, Julia, Specht, Katja et al. · 2016 · Nature Communications
98. Turning the corner on therapeutic cancer vaccines
    Hollingsworth, Robert E., Jansen, Kathrin · 2019 · npj Vaccines
99. RNA splicing factors as oncoproteins and tumour suppressors
    Heidi Dvinge, Eun Hee Kim, Omar Ibrahim Abdel-Wahab, Robert K. Bradley · 2016 · Nature reviews. Cancer
100. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
     Rolfo, Christian, Mack, Philip, Scagliotti, Giorgio V., Aggarwal, Charu, Arcila, Maria E., Barlesi, Fabrice, Bivona, Trever, Diehn, Maximilian, Dive, Caroline, Dziadziuszko, Rafal et al. · 2021 · Journal of Thoracic Oncology